NCT05061004ClinicalTrials.gov

Cephea Early Feasibility Study

قيد التجنيديقبل مشاركين الآن، وفقاً لسجل السجل.

التواصل مع هذه الدراسة

باختصار

The objective of this study is to evaluate the preliminary safety and effectiveness of the Cephea Mitral Valve System for the treatment of symptomatic patients with mitral valve disease (including mitral regurgitation, mitral stenosis and mixed mitral valve disease) in…

تدخّليةمطلوب 90 مشاركاً22 موقعاًدولتان

الفئات

القلب والأوعية الدموية100%

مسجَّلة في سجل واحد

ClinicalTrials.govNCT05061004فتح هذا السجل في ClinicalTrials.govتمت المزامنة الأسبوع الماضي

يمكن أن تُسجَّل دراسة واحدة في عدة سجلات. نعرضها مرة واحدة ونربط بكل سجل نحتفظ به.

تُعرض معلومات التجربة كما نشرها السجل، بلغتها الأصلية.

هل أنت مهتم بهذه الدراسة؟

تسجيل الدخول أو أنشئ حسابًا لتسجيل اهتمامك ومتابعة هذه الدراسة.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

Present: Registered before enrolment beganFirst posted 2021-09-29; recorded start 2022-04-28
Present: Has a defined primary outcomeA primary outcome measure is listed in the record
Present: The primary outcome states a time frameThe primary outcome measure records a time frame
Not stated: Participants are not randomly assignedAllocation is recorded as non-randomised
Not stated: A comparison group is not stated in the registry recordThe record describes a single study arm
Not stated: Open label (no blinding)Masking is recorded as none (open label)
Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
Present: Sponsor has 82 other studies in this databaseCounted from the lead sponsor named in the record (Abbott Medical Devices)
Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database

The record lists 1 condition.
Lead sponsor type recorded as: industry.

These are facts from the public registry record, not a judgement about the study. Discuss any trial with your own doctor before taking part.

What these facts mean, and what to ask · ruleset v1

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourEXPLORATORY

An exploratory-stage design for a study of this type, judged from its ClinicalTrials.gov record.

How this score is built

Randomised allocation0/20
Allocation not stated in the record
Blinding0/20
Open-label
Control arm0/15
No comparator arm stated in the record
Primary-outcome specificity10/10
Named primary outcome with a defined time frame
Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
Multi-centre8/8
Multi-centre: 22 sites
Data monitoring committee0/7
Data monitoring committee not stated in the record
Prospective registration5/5
Registered before the study start date
Protocol / SAP posted0/5
No protocol or SAP posted to the registry

ScaleSMALL

A small study, international in scope: 90 participants (target), run at 22 sites, across 2 countries.

How this score is built

Enrolment15/40
50 participants (target)
Site count16/25
22 sites
Country count7/15
2 countries
Planned duration10/10
Planned over about 108 months
Sponsor scale7/10
Abbott Medical Devices has led 83 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built

Investigator standing0/100
No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

ملخص

الحالات

Mitral Regurgitation

الأهلية

الأهلية
الجنس	الجميع
الأعمار	18 Years – لا حد أقصى
المتطوعون الأصحّاء	لا

الأهلية كما كُتبت في السجل

Key Inclusion Criteria: * Mitral valve disease resulting in mitral regurgitation (MR ≥ Grade III) and/or severe mitral valve stenosis (mitral valve area ≤ 1.5cm² and/or mean transmitral gradient ≥10 mmHg at normal heart rate) per American Society of Echocardiography criteria. * LVEF ≥ 30% * In the judgement of the Site Heart Team, transcatheter therapy is deemed more appropriate than open heart surgery. Key Exclusion Criteria: * Prior surgical or interventional treatment that interferes with the Cephea valve delivery or function. * Need for emergent or urgent surgery.

الأهلية في عبارات بسيطة

لم تُقسَّم معايير هذا السجل إلى عبارات منفصلة بعد. نص السجل أعلاه كامل وهو النسخة المُعتمَدة.

تصميم الدراسة

تصميم الدراسة
نوع الدراسة	تدخّلية
المرحلة	غير منطبق
التخصيص	غير منطبق
نموذج التدخّل	SINGLE_GROUP
الغرض الأساسي	TREATMENT
التعمية	NONE (0)
التجنيد	مطلوب 90 مشاركاً

الجهة الراعية والمتعاونون

Abbott Medical Devices الجهة الراعية

الأذرع والتدخلات

TreatmentEXPERIMENTAL
Treatment of symptomatic patients with mitral valve disease (including mitral regurgitation, mitral stenosis and mixed mitral valve disease) with the Cephea Mitral Valve System

التدخلات

جهاز Cephea Mitral Valve System
Transcatheter mitral valve replacement

مقاييس النتائج

مقياس النتيجة الأولي
Primary Safety Endpoint
Freedom from all-cause mortality, which will be assessed at 30 days post implant.
الإطار الزمني 30 days post implant
مقياس النتيجة الأولي
Primary Effectiveness Endpoint
Proportion of subjects with reduction of MR to ≤ Grade I, will be assessed at 30 days post implant.
الإطار الزمني 30 days post implant

التواريخ

التواريخ
تاريخ البدء	28 أبريل 2022 (فعلي)
الإتمام الأولي	31 ديسمبر 2026 (تقديري)
الإتمام	1 مارس 2031 (تقديري)
أول نشر	29 سبتمبر 2021 (فعلي)
آخر تحديث	11 سبتمبر 2026
النتائج منشورة	غير مذكور في سجل السجل
آخر تأكيد للحالة	ديسمبر 2025

فعلي يعني أن الحدث وقع. تقديري يعني أن الجهة الراعية تتوقعه. للكلمتين معنيان مختلفان.

المواقع

20 موقعاً قيد التجنيد

Canada

Canada
المنشأة	المدينة	الولاية أو المنطقة	الحالة
Institut de Cardiologie de Montreal	Montreal	Quebec	مكتمل
IUCPQ-ULaval	Québec	Quebec	مسحوب

United States

United States
المنشأة	المدينة	الولاية أو المنطقة	الحالة
University of Michigan - Davis Medical Center	Ann Arbor	Michigan	قيد التجنيد
Piedmont Heart Institute	Atlanta	Georgia	قيد التجنيد
Emory University Hospital	Atlanta	Georgia	قيد التجنيد
Atrium Health - Carolinas Medical Center	Charlotte	North Carolina	قيد التجنيد
Northwestern Memorial Hospital	Chicago	Illinois	قيد التجنيد
The Cleveland Clinic Foundation	Cleveland	Ohio	قيد التجنيد
Houston Methodist	Houston	Texas	قيد التجنيد
Cedars-Sinai Medical Center	Los Angeles	California	قيد التجنيد
Minneapolis Heart Institute	Minneapolis	Minnesota	قيد التجنيد
Ascension Saint Thomas	Nashville	Tennessee	قيد التجنيد
Vanderbilt Heart & Vascular Institute	Nashville	Tennessee	قيد التجنيد
New York-Presbyterian/Columbia University Medical Center	New York	New York	قيد التجنيد
Sentara Norfolk General Hospital	Norfolk	Virginia	قيد التجنيد
Banner-University Medical Center Phoenix	Phoenix	Arizona	قيد التجنيد
Allegheny General Hospital - ASRI	Pittsburgh	Pennsylvania	قيد التجنيد
University of California - Davis Medical Center	Sacramento	California	قيد التجنيد
Swedish Medical Center	Seattle	Washington	قيد التجنيد
Montefiore Medical Center - Moses Campus	The Bronx	New York	قيد التجنيد
Los Robles Regional Medical Center	Thousand Oaks	California	قيد التجنيد
Ascension Via Christi Hospitals Wichita	Wichita	Kansas	قيد التجنيد

مستندات الدراسة

لا تُرتبط أي مستندات في سجل السجل هذا.

التغيّرات عبر الزمن

11 سبتمبر 2026
تغيّر هدف التجنيد
Enrollment target revised up from 50 to 90
5090

السجل: ClinicalTrials.gov · NCT########

https://xmedica.io/trials/ctgov/NCT05061004